United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shopify

An investment in either of these two stocks could yield attractive returns for decades.

Have $3,000? 2 Smart Growth Stocks to Buy Right Now

Colgate-Palmolive

Clorox

ConocoPhillips

Costco

Lowe's

Main Street Capital

National Retail Properties

Realty Income Corp

Procter & Gamble

Pinnacle West Capital

Royal Bank of Canada

Texas Instruments

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: July 20-August 2, 2021

Pfizer (PFE) closed the most recent trading day at $40.15, moving -0.5% from the previous trading session.

Pfizer (PFE) Stock Moves -0.5%: What You Should Know

Based on a forecasted annual return of 3.2% and risk of 12% through 2026, Pfizer is a Hold.

Pfizer: The Wildcard

BioNTech SE

Co-Diagnostics

Moderna

Novavax

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Pfizer Inc. said Friday that the Food and Drug Administration accepted its application for full approval of the COVID-19 vaccine it developed with BioNTech SE . As part of the application process, the FDA sets a decision date based on the rules of the Prescription Drug User Fee Act for applications that receive what is called Priority Review.

Pfizer says FDA's decision to approve its COVID-19 vaccine is expected by January

Earlier this month, the FDA alerted that Pfizer Inc (NYSE:PFE) had voluntarily recalled its smoking cessation drug, Chantix, after finding elevated levels of cancer-causing nitrosamines.  In guidance released Friday, the FDA set an interim allowable limit for that compound in Chantix at 185 ng per milliliter to help ensure adequate drug supply in the U.S.

FDA Supports Limited Distribution Of Pfizer's Antismoking Pill, Chantix

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo has joined the company as Senior Vice President and Chief Investor Relations Officer, reporting to Chief Corporate Affairs Officer Sally Susman. Mr. Stevo succeeds Chuck Triano, Senior Vice President, Investor Relations, who previously announced his intent to retire after a successful 13-year period at Pfizer and a nearly 35-year career interacting with the global investment community. Mr. Triano will stay

Pfizer Announces New Investor Relations Leader

Valneva SE

Saint- Herblain ( France) and New York, NY , July 19 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. (NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate's pediatric program.

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

Cisco Systems

General Dynamics

Home Depot

Illinois Tool Works

Lockheed Martin

Merck

PepsiCo

SPDR S&P 500 ETF Trust

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for your consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.

10 Dividend Growth Stocks For July 2021

AbbVie

Biogen

There are important things to watch with each of these stocks.

4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021

It's the most likely winner benefiting from the most likely reason that an imminent crash might occur.

This Stock Should Soar If the Stock Market Crashes This Summer

Apple

Microsoft

Hexavest of Montreal reduced positions in Apple and Microsoft stock, and increased holdings in Pfizer and Merck in the second quarter.

Big Contrarian Investor Sold Apple, Microsoft Stock, Bought Pfizer and Merck

3 Things Every Investor Should Know About Pfizer's Dividend

LONDON--(BUSINESS WIRE)--For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021 (IAS 2021), being held virtually 18-21 July. The 2-drug regimen (2DR) Dovato (dolutegravir/lamivudine) demonstrated non-inferior efficacy compared to continuation of a current antiretroviral r

ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

LONDON--(BUSINESS WIRE)--For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive findings from the CUSTOMIZE (Cabotegravir plus Rilpivirine long acting in the US To Optimize and Measure Implementation and Experience) trial. The study, which included people living with HIV and healthcare teams and overlapped with the COVID-19 pandemic, demonstrate

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

The FDA has granted priority review designation for Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) full approval application of their partnered COVID-19 vaccine, putting it on track for potential full approval by early next year. The goal date for a decision is January 2022.

Pfizer - BioNTech COVID-19 Vaccine Granted Priority Review By FDA

Pfizer Inc (NYSE: PFE) has agreed to pay $345 million to resolve claims by consumers claiming they overpaid for EpiPens due to anti-competitive and unfair practices, reports Reuters. The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas.

Pfizer To Pay $345M To Resolve EpiPen Pricing Lawsuit: Reuters

Should Investors Worry About the Pfizer-BioNTech Vaccine's Lower Efficacy Against the Delta Variant?

Enterprise Products Partners

Innovative Industrial Properties

Their dividends are attractive. And their growth prospects are, too.

3 Dividend Stocks That Could Make You Richer in July (and Beyond)

While antibodies are not the only measure of a vaccine's effectiveness the study likely adds to the growing pool of evidence that mRNA vaccines may offer more robust protection.

Pfizer's Covid-19 Vaccine Generated 10 Times More Antibodies Than China's Sinovac Shot, Hong Kong Study Shows

Pfizer has indicated that a third dose of its vaccine may be needed within six to 12 months after full vaccination, as initial immunity wanes and as new and more aggressive variants of the Coronavirus continue to spread. The company says that it has preliminary data to prove that an additional dose.

What's New With Pfizer's Covid-19 Vaccine?

A very public regulatory debate about COVID-19 booster shots has seemingly put Pfizer at odds with federal health officials who say it's not necessary to get another shot at this time.

Pfizer is making the case for COVID-19 boosters. Health officials say we don't need a third dose yet.

News for Pfizer Stock (PFE)